Literature DB >> 3957897

Subunit structure and multiple phosphorylation sites of phospholamban.

T Imagawa, T Watanabe, T Nakamura.   

Abstract

The phosphorylation-induced mobility shift of the high molecular weight form of phospholamban (24,500 daltons) in the cardiac sarcoplasmic reticulum produced on 3',5'-cyclic AMP (cAMP)-dependent phosphorylation with 5 mM ATP was resolved into five clear steps on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and on Ca2+-calmodulin-dependent phosphorylation into ten steps. The mobility shift of the low molecular weight form of phospholamban (less than 14,400 daltons) in these reactions occurred in one step and two steps, respectively. With the two protein kinase activities, the electrophoretic pattern of the mobility shifts of the high and low molecular weight forms of phospholamban was similar to that obtained with Ca2+-calmodulin-dependent protein kinase alone. The results of pulse-chase experiments involving the centrifuge column method suggested that the site(s) of phosphorylation by cAMP- and Ca2+-calmodulin-dependent protein kinase activities are on the same phospholamban molecule. Two-dimensional tryptic peptide maps of phosphorylated phospholamban indicated that cAMP-dependent protein kinase phosphorylates at a single site, A, and Ca2+-calmodulin-dependent protein kinase phosphorylates at sites C1 and C2 in the low molecular weight form, where A is different from C1 but may be the same as C2. The high molecular weight form of phospholamban is suggested to be a pentamer of identical monomers (low molecular weight form) having one phosphorylation site for cAMP-dependent protein kinase and two for Ca2+-calmodulin-dependent protein kinase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3957897     DOI: 10.1093/oxfordjournals.jbchem.a135478

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  7 in total

1.  Recombinant tobacco mosaic virus movement protein is an RNA-binding, alpha-helical membrane protein.

Authors:  L M Brill; R S Nunn; T W Kahn; M Yeager; R N Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Complete complementary DNA-derived amino acid sequence of canine cardiac phospholamban.

Authors:  J Fujii; A Ueno; K Kitano; S Tanaka; M Kadoma; M Tada
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

3.  Structure of the 1-36 amino-terminal fragment of human phospholamban by nuclear magnetic resonance and modeling of the phospholamban pentamer.

Authors:  P Pollesello; A Annila; M Ovaska
Journal:  Biophys J       Date:  1999-04       Impact factor: 4.033

4.  Characterization of the molecular form of cardiac phospholamban.

Authors:  J M Harrer; E G Kranias
Journal:  Mol Cell Biochem       Date:  1994-11-23       Impact factor: 3.396

Review 5.  Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization.

Authors:  P V Sulakhe; X T Vo
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

6.  Dimerization of recombinant tobacco mosaic virus movement protein.

Authors:  Laurence M Brill; Songpon Dechongkit; Byron DeLaBarre; Jonathon Stroebel; Roger N Beachy; Mark Yeager
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  Cardiac-specific deletion of voltage dependent anion channel 2 leads to dilated cardiomyopathy by altering calcium homeostasis.

Authors:  Thirupura S Shankar; Dinesh K A Ramadurai; Kira Steinhorst; Salah Sommakia; Rachit Badolia; Aspasia Thodou Krokidi; Dallen Calder; Sutip Navankasattusas; Paulina Sander; Oh Sung Kwon; Aishwarya Aravamudhan; Jing Ling; Andreas Dendorfer; Changmin Xie; Ohyun Kwon; Emily H Y Cheng; Kevin J Whitehead; Thomas Gudermann; Russel S Richardson; Frank B Sachse; Johann Schredelseker; Kenneth W Spitzer; Dipayan Chaudhuri; Stavros G Drakos
Journal:  Nat Commun       Date:  2021-07-28       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.